Using Ozempic (semaglutide) with insulin increases the risk of hypoglycemia (dangerously low blood sugar). Both medications lower blood glucose through different mechanisms, and their combined effect can cause blood sugar to drop too low, especially when starting Ozempic or changing doses.
How This Interaction Works (Mechanism)
Semaglutide (Ozempic) is a GLP-1 receptor agonist that stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, and slows gastric emptying. When added to exogenous insulin therapy, the combined insulin effect (both endogenous stimulation from semaglutide and exogenous injection) can exceed the body's glucose supply, causing hypoglycemia. The delayed gastric emptying can also alter the timing of glucose absorption from meals.
Source: Ozempic (Semaglutide) Prescribing Information, Novo Nordisk, 2025
When starting Ozempic in a patient already on insulin, the insulin dose typically needs to be reduced by 10 to 20 percent to prevent hypoglycemia. Monitor blood glucose frequently during the transition period. Learn to recognize hypoglycemia symptoms: shakiness, sweating, confusion, rapid heartbeat, and dizziness. Always carry a fast-acting glucose source. Work closely with your endocrinologist on dose adjustments.
Check More Drug Interactions
Use our free interaction checker to search thousands of drug, supplement, and food combinations.
Open Interaction CheckerGear GLP-1 users buy most
As an Amazon Associate I earn from qualifying purchases.
Sources and standards behind this page
What a drug interaction does, and how strongly it is supported, is documented in public labeling and federal safety references rather than in any one summary, and the sources below are the primary ones. They are linked so a reader can check a claim without taking this page's word for it.
- DailyMed carries the current FDA labeling for every marketed drug product, including the warnings and drug interaction sections.
- Drugs@FDA is the federal database of approved drug products and their approval documents.
- FDA: Drug interactions, what you should know explains how drug-drug, drug-food and drug-condition interactions are described on labels.
- FDA Drug Safety Communications publishes the agency's safety alerts and label changes as they are issued.
- FDA MedWatch is the program for reporting and reviewing adverse events, including suspected interactions.
- openFDA provides public access to FDA labeling and adverse event data.
- MedlinePlus drug information is the National Library of Medicine's consumer reference for what a medicine is and how it is taken.
- NIAAA: Harmful interactions documents which medicines interact with alcohol and how.
- NCCIH: Herb-drug interactions summarises the evidence on interactions between herbal products and medicines.
- National Library of Medicine maintains the drug and health databases the sources above draw on.
This page describes how this interaction works and where it is documented. It is not medical advice: a prescriber or pharmacist decides what applies to a particular patient and medication.
Frequently Asked Questions
Ozempic and Insulin have a moderate interaction that requires caution. While some patients may take both under medical supervision, the combination can cause adverse effects. Talk to your doctor before combining these medications, and do not adjust doses on your own.
Using Ozempic (semaglutide) with insulin increases the risk of hypoglycemia (dangerously low blood sugar). Both medications lower blood glucose through different mechanisms, and their combined effect can cause blood sugar to drop too low, especially when starting Ozempic or changing doses.
Yes. Anytime you are taking multiple medications, supplements, or substances, you should inform your doctor and pharmacist. They can evaluate your specific risk factors (age, kidney function, other medications, medical conditions) and determine whether the Ozempic and Insulin combination is safe for you, or whether adjustments are needed.
Related Resources
Get Drug Safety Alerts
Leave your email for updates on FDA warnings, new drug interactions, and patient safety information. We have not started sending yet, and we will only email when we do.